Resverlogix Corp. (TSX: RVX) (“Resverlogix” or the “Company”) today announces that because of delays in the completion of its year-end ...

As tuition rises, financial aid has expanded, but without significantly altering who benefits. The Chronicle took a closer look at federal and institutional data to see how that trend has played out.

Record annual revenue and adjusted EBITDA of $257.8 million and $103.1 million; annual EPS (diluted) $1.43 Strong high -value ...

Q25: Ending the year with strong growth momentum, with broad-based acceleration across key metrics.TPV at an all-time quarterly high of US$13.1 ...

The Company Generated $2.9 Million in Free Cash Flow During the Quarter, Marking Significant Improvements Year Over Year and Sequentially. Over the Past 12 Months, the Company ...

Settling with businesses that claimed the Victorian government was responsible for damage caused by COVID-19 lockdowns avoids a trial ahead of the state election.

Record annual revenue and adjusted EBITDA of $257.8 million and $103.1 million; annual EPS (diluted) $1.43Strong high value registration activity in the Saskatchewan Land Registry, supported by favour ...

Q25: Ending the year with strong growth momentum, with broad-based acceleration across key metrics. TPV at an all-time quarterly high of US$13.1 billion, growing 70% year-over-year, the fifth straight ...

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the ...

Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases ...

The Board of Fidelity European Trust PLC (the “Company”) recommends a final dividend of 6.00 pence which together with the interim dividend payment of 3.90 pence per share (totalling 9.90 pence) ...

Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) ...